AI Article Synopsis
- Hepatocellular carcinoma (HCC) is a significant global health concern, characterized by late diagnosis and high recurrence rates, necessitating early detection through specific biomarkers.
- Glypican-3 (GPC-3) is identified as a promising biomarker for HCC, being overexpressed in various tumors, which opens up opportunities for targeted therapies to enhance treatment outcomes.
- Recent advancements in GPC-3-targeted therapies, such as bi-specific antibodies and CAR T cell therapies, underscore its potential as both a diagnostic and therapeutic tool in the fight against HCC.
Article Abstract
Hepatocellular carcinoma (HCC) is a global health issue due to its late diagnosis and high recurrence rate. The early detection and diagnosis of HCC with specific and sensitive biomarkers and using novel treatment approaches to improve patient outcomes are essential. Glypican-3 (GPC-3) is a cell surface proteoglycan that is overexpressed in many tumors, including HCC. GPC-3 could be used as a specific biomarker for HCC early detection and could be a potential target for precise therapeutic strategies. Effective identification of GPC-3 could improve both diagnosis and targeted therapy of HCC. Moreover, targeted therapy using GPC-3 could result in a better treatment outcome. Recently, GPC3-targeted therapies have been used in different investigational therapeutic approaches like bi-specific/monoclonal antibodies, peptide vaccines, and CAR T cell therapies. This study aims to highlight the theranostic potential of GPC-3 as a novel biomarker for early detection and as a potential molecular target for HCC treatment as well.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.yexcr.2024.114391 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!